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mphetamines and ring substituted methylene-
dioxyamphetamines are the most commonly used illicit
drugs after cannabis. Amphetamines are psychostimu-
lants, and methylenedioxyamphetamines are entacto-
gens—psychoactive drugs with emotional and social
effects. Both drug groups are derivatives of β-phenethy-
lamine and they share chemical and pharmacological
similarities (Figure 1). 3,4-methylenedioxymethamphet-
amine (MDMA, ecstasy) is the most popular entactogen,
and methamphetamine (METH, speed) is the most pop-
ular stimulant. In Germany about 5% of young adults
have used these drugs at least once.
1 However, this per-
centage is 5 to 10 times higher among people who regu-
larly attend parties and raves, and seems to be generally
higher in other countries such as the UK and USA.
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Ecstasy (MDMA, 3,4-methylendioxymethamphetamine) and the stimulants methamphetamine (METH, speed) and
amphetamine are popular drugs among young people, particularly in the dance scene. When given in high doses
both MDMA and the stimulant amphetamines are clearly neurotoxic in laboratory animals. MDMA causes selective
and persistent lesions of central serotonergic nerve terminals, whereas amphetamines damage both the serotoner-
gic and dopaminergic systems. In recent years, the question of ecstasy-induced neurotoxicity and possible functional
sequelae has been addressed in several studies in drug users. Despite large methodological problems, the bulk of evi-
dence suggests residual alterations of serotonergic transmission in MDMA users, although at least partial recovery
may occur after long-term abstinence. However, functional sequelae may persist even after longer periods of absti-
nence. To date, the most consistent findings associate subtle cognitive impairments with ecstasy use, particularly with
memory. In contrast, studies on possible long-term neurotoxic effects of stimulant use have been relatively scarce.
Preliminary evidence suggests that alterations of the dopaminergic system may persist even after years of abstinence
from METH, and may be associated with deficits in motor and cognitive performance. In this paper, we will review
the literature focusing on human studies. 
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in underground laboratories. Ecstasy is almost always
sold as tablets or pills with various imprinted logos
(Figure 2). The pills typically contain 70 to 120 mg of
MDMA, although the concentration may sometimes be
higher or lower. Occasionally ecstasy tablets will contain
similarly acting analogues (3,4-methylenedioxy-N-
ethylamphetamine [MDE], 3,4-methylenedioxyamphet-
amine [MDA], or 3,4-methylenedioxy-alpha-ethyl-
N-methylphenethylamine [MBDB], Figure 1) or
amphetamines, and more rarely they may also contain
substances from different classes. Amphetamines are
mostly sold as powder which can be inhaled, smoked,
ingested, or injected, although intranasal use (“snort-
ing”) is now particularly common.
The acute pharmacology of MDMA and amphetamines
has been widely studied.
6Among other actions, both drug
groups bind to presynaptic monoamine transporters, and
act as inhibitors on these sites and releasers of the endoge-
nous monoamines from presynaptic terminals. The main
mechanism of amphetamines is the enhanced release of
dopamine (DA), particularly in the striatal system, and
norepinephrine (NE). MDMA binds most strongly to the
serotonin (5-HT) transporter (SERT) and induces rapid
and powerful release of both 5-HT and DA.
Depending on the dose and route of administration,
effects of stimulants may last from 3 to about 8 hours.
They include increased drive, hypervigilance, pressure of
ideas and speech, euphoria, and expansive behavior, but
sometimes dysphoric mood, agitation, and aggression
may occur. The psychological effects of MDMA last
about 3 to 5 hours, and are more complex: they include
relaxation, feelings of happiness, empathy, and closeness
to other people, along with stimulant-like effects, alter-
ations of perception, and other mild hallucinogenic
effects.
7
The addictive potential of amphetamines is generally
lower than that of cocaine or heroin, but it becomes high
when the drugs are used intravenously. MDMA is con-
siderably less addictive, and is mostly used as a recre-
ational drug during weekends; however, a minority of
about 15% to 20% of users develop a more frequent or
compulsive use pattern, and they may ingest 10 or even
more pills per occasion.
8 Beside the issue of addiction,
there is a range of acute and subacute complications
including drug-induced psychoses, seizures, myocardial
infarction, or stroke resulting from hypertension and/or
hemorrhage, hyperpyrexia with rhabdomyolysis, dis-
seminated intravascular coagulation (DIC) and organ
failure, toxic hepatitis, and many others. Moreover,
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Figure 1. Chemical structures of amphetamines and ring-substituted
methylenedioxyamphetamines (ecstasy). MDMA, methylene-
dioxymethamphetamine; MDE,   3,4-methylenedioxy-N-
ethylamphetamine; MDA, 3,4-methylenedioxyamphetamine;
MBDB, 3,4-methylenedioxy-alpha-ethyl-N-methylphenethy-
lamine
R1 = CH3; R2 = CH3: MDMA   
R1 = H; R2 = CH: MDA  
R1 = C2H5; R2 = CH3: MDE 
R1 = CH3; R2 = C2H5: MBDB 
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Selected abbreviations and acronyms
5-HT serotonin
5-HIAA 5-hydroxyindoleacetic acid
DA dopamine
MDMA methylenedioxymethamphetamine (ecstasy)
METH methamphetamine
SERT serotonin transporter
Figure 2. Ecstasy pills from the illicit market.
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rotoxic in animal studies, particularly when given at high
and repeated doses. This neurotoxic potential of the
drugs may be relevant for humans. In the following sec-
tions we review the evidence for neurotoxicity in animal
studies and in human populations.
Animal studies
Brain morphology and neurochemistry 
Several studies in different laboratories and with differ-
ent species demonstrate long-term alterations in brain
5-HT systems following high and repeated doses of
MDMA. In studies with primates, even single doses of
MDMA were found to elicit some degree of serotoner-
gic depletion lasting over a few weeks.
4 However, the
lowest MDMA dose which was shown to produce long-
term neurotoxic effects that persisted over months and
years has been 5 mg/kg given parenterally twice daily
over 4 days, ie, 40 mg/kg overall in 4 days.
9-11The alter-
ations include depletion of 5-HT and its major metabo-
lite 5-hydroxyindoleacetic acid (5-HIAA), reduced
[3H]paroxetine binding, reflecting reduced density of
SERT, and reduced serotonergic axonal density in sev-
eral brain regions.
6-12 All but one species tested so far,
including nonhuman primates, have confirmed the pat-
tern of selective neurotoxicity for serotonergic axons,
with the sole exception of mice, which exhibit neurotoxic
alterations of serotonergic and dopaminergic axons.
4The
rate of recovery was shown to be region-dependent. This
probably corresponds to the very different distances that
must be covered in the process of reinnervation. Axons
need to be regrown from their origin in the serotonergic
cell bodies in the raphe nuclei of the brain stem to the
different terminal areas of the brain. In rats, full recov-
ery was shown in most studies and most brain regions
after 1 year, but some individual studies reported only
partial recovery in the hippocampus and some cortical
areas and hyperinnervation in the hypothalamus. In non-
human primates, sensitivity to the neurotoxic effects of
MDMA was shown to be more pronounced than in
rodents, resulting in higher rates of 5-HT depletion with
smaller doses of MDMA and persisting hypoinnervation
patterns in most neocortical regions and the hippocam-
pus in the range of 20% to 40% lower SERT binding
depending on the brain region examined) for as long as
7 years post-treatment.
9-11
Similarly to MDMA, stimulant amphetamines, particularly
METH, have also been shown to be neurotoxic in rodent
and nonhuman primate studies.
6,13 Typical neurotoxic
METH regimens are 5 to 10 mg/kg given parenterally 4 to
10 times within 1 to 4 days. Stimulant-related neurotoxic-
ity is not restricted to the serotonergic system. High and/or
repeated doses of METH induce widespread degenera-
tion of presynaptic serotonergic axon terminals and degen-
eration of dopaminergic terminals, which is most promi-
nent in the striatum. The consequences are 5-HT and
dopamine (DA) depletion, and lower 5-HT and DA trans-
porter densities (SERT and DAT) in brain tissue, with the
effects being more pronounced on the striatal DA sys-
tem.
6,13-15A recent study in vervet monkeys used an esca-
lating-dose METH exposure which models a common
human abuse pattern, and demonstrated persistent
changes in the presynaptic striatal DA system 3 weeks
after abstinence (20% lower striatal DA content, 35%
lower DAT binding).
16 However, METH toxicity to DA
and 5-HT terminals had been previously shown to be con-
siderably more long-lasting, and can persist for up to 4
years after drug administration in nonhuman primates.
17
The mechanism of neurotoxicity resulting from amphet-
amines and MDMA is not entirely understood.
However, data from animal studies strongly suggest that
the formation of free radicals is a key factor, that hyper-
thermia enhances the formation of free radicals, and that
both hyperthermia and high ambient temperatures
enhance the neurotoxic effects of the drugs.
4-6
Functional consequences of neurotoxic drug regimens
Generally, the long-term functional abnormalities seen
in laboratory animals after neurotoxic MDMA regi-
mens have been only subtle.
18-20This may correspond to
a complex role of the neuromodulator 5-HT in “fine
tuning” and stabilizing neural transmission in cerebral
networks.
21-22 Broadly speaking, 5-HT appears to play
important roles in several functional systems such as
cognition, stimulus processing, psychological well-being,
sleep control, and vegetative and neuroendocrine func-
tions, without it being critical for the essential func-
tioning of any of these domains. Nevertheless, some
studies which used specialized behavioral test methods
and pharmacological challenges reported subtle func-
tional disturbances such as increased anxiety and poor
memory performance in MDMA-treated rodents and
monkeys.
19-20,23-30 However, other studies reported normal
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lowing MDMA treatment,
31-33 and studies which used
behavioral tests for the assessment of anxiety and risk-
taking behavior yielded conflicting results.
27-28,34-35 These
data strongly suggest that if ecstasy users are indeed suf-
fering neurotoxic damage to their serotonergic system,
the functional consequences may be subtle. 
Similarly, neurotoxic METH regimens which are suffi-
cient to produce neurotoxicity were shown to induce
only moderate, if any, alterations in behaviour of labo-
ratory animals. These moderate effects may be best
explained by the fact that METH-induced degenera-
tion of DA and 5-HT axon terminals is incomplete and
that long-term reductions in monoamine concentration
levels and transporter densities are in the range of 20%
to 45%.
16,36 Indeed, higher reductions in the range of
80% to 95% may be required to produce gross abnor-
malities such as parkinsonian-like motor deficits.
Accordingly, reduction of spontaneous locomotor activ-
ity was reported only 3 days after a neurotoxic METH
regimen, but not after 1, 2, and 4 weeks in rodents.
33
However, using more subtle motor tests, persisting
deficits in active avoidance performance (24% increase
in response latency) and balance beam performance (2-
to 3-fold increase in footfalls) were demonstrated.
36 In
mice, an impairment of consolidation of learned place
preference was reported after neurotoxic METH
doses.
37 Rats treated with a neurotoxic regimen of
METH were impaired on a radial maze sequential
learning task when tested after 3 weeks,
38 and on a nov-
elty preference object recognition (OR) task when
tested after 1 week and 4 weeks.
39-40 Interestingly, a
recent study reported than an escalating dose regimen
which appears to mimic a common human pattern of
escalating drug intake attenuates the neurotoxic effects
and the OR deficits after METH treatment.
41 Similarly,
in nonhuman primates progressive increases in METH
doses in an escalating dose regimen induced abnormal
behavior and decreases in social behavior on “injec-
tion” days with aggression decreasing throughout the
study; however, after 3 weeks of abstinence no differ-
ences in baseline vs post-METH behaviors were
observed.
16 These recent studies suggest that many
METH users may not present with functional abnor-
malities despite residual dopaminergic toxicity; how-
ever, the extent of toxic damage and functional seque-
lae may well be more severe in heavy users with binge
use behavior. 
Are the animal data relevant for humans?
The key question is whether illicit drug users may suffer
similar neurotoxic brain lesions as experimental animals.
Over the last 10 to 15 years this question has received par-
ticular attention for MDMA,
42 while studies with amphet-
amine users very been relatively scarce. Two reasons may
account for the relatively lower interest in amphetamine-
related neurotoxicity in humans: first, the neurotoxic doses
in experimental animals are much higher than the typical
human recreational doses of 20 to 40 mg of AMPH or
METH, and second, amphetamines have been used ther-
apeutically for the treatment of attention deficit-hyperac-
tivity disorder (ADHD) and narcolepsy for decades with-
out clear evidence of long-term adverse effects.
43 Hence,
the interest in possible long-term sequelae of neurotoxic
drug use has focused highly on MDMA.
Compared with a neurotoxic MDMA regimen in pri-
mates (5 mg/kg twice daily over 4 days sc or ip the typi-
cal dose of a recreational MDMA weekend user (1 to 2
pills of 75 to 125 mg MDMA or analogue every 1 to 4
weeks) is still considerably lower.
44 However, according
to some formulae for interspecies scaling, the recre-
ational MDMA doses might well approach doses com-
monly given to animals in experimental studies.
4
Moreover, some heavy users take MDMA more fre-
quently than just at weekends; they ingest up to 10 or
even more pills in one night and they typically use
MDMA over years, which may increase the risk for
long-term cumulative neurotoxic effects. Although these
heavy users are a minority, given the widespread use of
MDMA, their absolute number is large. Interestingly, a
study which looked at the effects of self-administration
of MDMA in primates over a period as long as 18
months showed 5-HT depletions in the order of 25% to
50% lower (5-HT concentration depending on the
region examined, in various cortical and subcortical
regions.
45 These decrements in 5-HT content did not
reach statistical significance, possibly due to the small
sample in this study (n=3). Nevertheless, if the results are
confirmed by further studies, they are clearly alarming.
45
Furthermore, the widespread parallel use of different
neurotoxic substances such as MDMA, METH, and
alcohol may act synergistically and enhance the neuro-
toxic effects of the single drugs. Finally, neurotoxicity
may be enhanced by the typical conditions associated
with MDMA and METH use such as hot, overcrowded
surroundings and long periods of dancing, leading to fur-
Translational research
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46 In conclusion, it is
possible that the animal data demonstrating MDMA
and METH-induced neurotoxicity are indeed relevant
for humans, and that club drug users may be exposing
themselves to the risk of neurotoxic brain damage. 
Studies in ecstasy users
Brain morphology and global brain function
In principle, it is rather unlikely that neurotoxic damage
confined to the serotonergic system will be visible in
routine brain imaging procedures in terms of loss of
brain volume or atrophy, or that it will manifest itself as
an alteration of global cerebral activity in positron emis-
sion tomography and single–photon emission tomogra-
phy (PET and SPECT). However, serotonin is more
than a neurotransmitter or neuromodulator in neuronal
tissues; it also exerts powerful vasoconstrictive actions
on small brain vessels,
47 has neurotrophic effects on brain
tissue not confined to the period of brain maturation,
48
and has been shown to stimulate neurogenesis in the
hippocampus throughout adulthood.
49
Routine structural magnetic resonance imaging (MRI),
perfusion and diffusion MRI, SPECT with 
133Xe, and
99mTc-hexamethylpropylene amine oxime (HMPAO) and
H2
15O PET were generally found to be normal in ecstasy
users.
50-53 However, one study reported an association
between longer periods of MDMA use and decreased
global brain volume,
50 and another study
54 demonstrated
reduced grey matter density in several cortical regions.
In addition, studies with MR spectroscopy reported
higher concentration of the glia marker myoinositole
with heavier use of MDMA,
55 dose-dependent reduc-
tions of N-acetylaspartate (NAA) levels (NAA:creatine
and NAA:choline ratios) in the frontal cortex of
MDMA users,
56 and a tendency towards lower NAA:cre-
atine ratios in the hippocampus of MDMA users com-
pared with controls.
57These findings could be related to
neurotoxic damage and glial proliferation, indicating a
repair mechanism. In addition, another small pilot study
reported a high diffusion coefficient (ADC) and high
regional cerebral blood volume (rCBV) in the globus
pallidus, a brain area that is particularly rich in 5-HT.
This finding could be related to vasodilatation due to
low serotonergic tone following degeneration of sero-
tonergic axons.
52 Recently, a large study with 71 ecstasy
polydrug users reported alterations in the thalamus asso-
ciated specifically with MDMA use: decreased fractional
anisotropy (FA) in diffusion tensor imaging (DTI) was
suggestive of axonal loss; whereas increased regional
cerebral blood volume (rCBV) in perfusion weighted
imaging (PWI) may have been caused by 5-HT deple-
tion.
58 In the same study no effects of ecstasy use on
apparent diffusion coefficients and brain metabolites
(MR spectroscopy) were detected. 
Finally, an ambitious and methodologically sound
prospective study examined a large number of young
subjects who socialized in the drug scene, but had not
yet used amphetamines or ecstasy (The Netherlands
XTC Toxicity [NeXT] study).
59 After a mean period of
17 months' follow-up, neuroimaging was repeated in 59
incident ecstasy users and 56 matched persistent
ecstasy-naives using multiple NMR techniques and
SPECT for measurement of SERT availability.
Although the novice MDMA users reported only very
sporadic and low-dose use of MDMA in the follow-up
period (mean 6.0, median 2.0 tablets), the MRI exami-
nations showed decreases in rCBV in the globus pal-
lidus and putamen (PWI), decreases in FA (indicator of
axonal integrity) in the thalamus and frontoparietal
white matter (DTI) and increases of FA in globus pal-
lidus, and increase of apparent diffusion coefficient in
the thalamus. Although relatively subtle, these findings
are alarming, because they are in line with sustained
effects of ecstasy on brain microvasculature, white mat-
ter maturation, and possibly axonal damage, even after
very low dosages of ecstasy.
59
Central serotonergic parameters
Reduced 5-HT concentration would be the expected
outcome of widespread neurotoxic damage of seroton-
ergic axon terminals in the brain tissue of MDMA users.
As the 5-HT concentration cannot be measured in vivo
in human brains, we may use the concentration of both
5-HT and its main metabolite, 5-HIAA, in cerebrospinal
fluid (CSF) as a proxy for the concentration in the brain.
An early study on a small number of ecstasy users
reported normal levels of 5-HIAA in the CSF.
60 Since
then several studies with larger samples showed reduced
concentrations of 5-HIAA in cerebrospinal fluid of
ecstasy users compared with control groups.
61-64 However,
only one study reported a correlation between the 5-
HIAA concentration and the extent of earlier ecstasy
use.
62
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examination of brain tissue receptors and/ or binding
sites feasible. An early PET study in 14 ecstasy users and
the SERT ligand [
11C] (+)McN5652 demonstrated a
dose-dependent reduction in its binding, both globally
and in most cortical and subcortical brain regions exam-
ined.
65 A further study in 10 ecstasy users also demon-
strated reduced cortical SERT availability using SPECT
and the SERT ligand β-CIT.
66 However, correlations
between the SERT availability results, cumulative
ecstasy consumption, and length of abstinence periods
suggested a temporary occupation or downregulation of
the binding site rather than structural neurotoxic dam-
age.
66 Since then there has been some debate on the
validity of SPECT and PET techniques with SERT lig-
ands in measuring MDMA-related neurotoxicity and on
additional subject-related methodological problems of
these early studies. Nevertheless, all but one more recent
studies with refined methods
67 and larger samples (up to
61 current and former users
68) confirmed reduced SERT
availability at least in female current users with a rela-
tively heavy use pattern (>50 pills),
58-68-72 and only one
small study with 12 former MDMA users was negative.
73
All in all, alterations were less pronounced in male users,
and were absent in former users following abstinence
from MDMA use of at least 12 months. A small longitu-
dinal study with two follow-up (+)McN5652-PET exam-
inations confirmed the reversibility of alterations of
SERT availability with a decrease in the intensity of
MDMA consumption.
74 In summary, these studies indi-
cate that women may be more susceptible to MDMA-
induced alterations of the serotonergic system than men,
and, in addition, they suggest at least some degree of
recovery of the assumed serotonergic lesion following
abstinence. 
Interestingly, another SPECT study with the 5-HT2A
receptor ligand [
123I]-R91150 demonstrated reduced cor-
tical binding in current ecstasy users with short-term
abstinence and increased binding in former users who
had not used ecstasy for an average of 5 months.
75 This
pattern is in line with animal data showing temporary
(up to 1 month) downregulation of postsynaptic 5-HT2
receptors resulting from high synaptic 5-HT concentra-
tion after administration of MDMA, and long-lasting
upregulation of the same postsynaptic receptors follow-
ing widespread presynaptic damage of serotonergic neu-
rons leading to 5-HT depletion.
76-77 Hence, unlike the
SERT data, postsynaptic receptor data suggest that
alterations of serotonergic systems may persist over long
periods of time in abstinent MDMA users. Such subtle
residual changes could be functionally important, and
might contribute to clinical or subclinical alterations of
psychological well-being and behavior of ecstasy users.
Serotonin-related functions
The neuromodulator 5-HT is involved in several func-
tional systems of the CNS. Consequently, damage to the
central serotonergic system could be theoretically fol-
lowed by disturbances in different fields such as psycho-
logical well-being, neuroendocrine secretion, vegetative
functions, processing of sensory stimuli, sleep architec-
ture, and cognition. In the last 10 to 12 years there have
been numerous studies demonstrating group differences
between ecstasy users and controls in virtually all these
fields, and differences favor the control groups in almost
every study.
44 However, results have been inconsistent
and several methodological problems (eg, pre-existing
differences, polydrug use, differences in lifestyle) make it
difficult and sometimes even impossible to draw firm
conclusions from the data. The majority of studies report
on psychopathology and cognition. Hence, in the follow-
ing sections we will focus on these subjects.
Psychopathology
A low serotonergic tone has been widely associated with
psychological disturbances, particularly with depression,
suicidality, aggressiveness, and impulsiveness. There are
several anecdotal reports of depressive syndromes, anx-
iety, and psychotic episodes associated with ecstasy use,
78
and high psychiatric comorbidity was established in stud-
ies with large samples of ecstasy-experienced polydrug
users.
79-80 A causal link between these disorders and
ecstasy may exist at least in a predisposed subgroup of
users. However, due to the widespread use of ecstasy and
the parallel use of other substances no firm conclusion
can be drawn from these reports. Moreover, results from
a prospective-longitudinal investigation on a large rep-
resentative sample of adolescents and young adults
(n=2462) over 4 years confirmed a high psychiatric
comorbidity in MDMA users, but demonstrated that the
use of ecstasy started, in most cases, after the onset of the
comorbid disorder.
81
Several studies used standardized psychometric instru-
ments and demonstrated higher scores for impulsiveness,
Translational research
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seeking, hostility/ aggression, and an overall heightened
level of psychological distress in mostly polydrug ecstasy
users compared with control groups.
44 However, results
have not been entirely consistent; for example, one study
reported reduced impulsiveness and aggression com-
pared with the control group.
63 Two studies suggested a
link between high scores and heavy parallel cannabis
use.
82-83 Moreover, in a recent study with a longitudinal
design and a follow-up period of 18 months increases in
self-rated psychopathology were associated with con-
tinued cannabis rather than continued ecstasy use.
84
Finally, in recent studies with relatively large samples of
234, 61, and 50 polydrug ecstasy users and controls using
other drugs only, elevated psychopathology appeared to
be associated with polydrug use in general and not
specifically with ecstasy use.
68,85-86
All in all, it is still unclear whether the frequently
reported emotional instability and impulsive features
and/ or the overall high level of psychological distress
result from ecstasy use or from the combined use of sev-
eral substances, or whether alternatively these are factors
predisposing to a general affinity to drugs. Interestingly,
a recent combined SPECT and psychometric study
established decreased SERT availability only in current
MDMA users, but elevated depression scores in current
and former users.
87 In this study, higher depression scores
were associated with higher lifetime MDMA dose, but
there was no association of psychometric scores with
SERT availability.
87 Finally, another study suggests an
interaction between genetic factors and the effects of
MDMA use on mood (high depression scores only in
ecstasy users carrying the s allele of the SERT encoding
gene but not in users with the ll genotype).
88These find-
ings underline the complexity of the issue and are in line
with animal data showing different long-term effects of
MDMA on anxiety in rats depending on the level of their
baseline anxiety, and only a loose association between the
neurotoxic effects of MDMA and its long-term impact
on anxiety-related behavior.
4,27-28,89 In conclusion, the link-
age between ecstasy-induced neurotoxicity and psycho-
logical problems does not seem to have been established
at this stage.
Cognition
Although our understanding of the role of serotonin in
cognitive processes is incomplete, there are indications
that serotonergic neurotransmission may particularly
interfere with an individual's cognitive style (impulsive
vs systematic) as well as with memory and learning
processes.
90-91 Indeed, relative deficits of short-term or
working memory, episodic memory and learning, as well
as increased cognitive impulsivity and diminished exec-
utive control, were frequently reported in ecstasy
users.
44,92
To date, the most consistent finding is that of subtle
deficits in episodic memory and learning abilities.
Numerous cross-sectional studies demonstrated relative
impairments of learning and memory performance and
only a small minority of studies reported no differences
between ecstasy users and controls or small and insignif-
icant differences after adjusting for possible con-
founders.
44,92-93 In general, poor memory was associated
with a heavier pattern of ecstasy use, although a minor-
ity of studies reported an association of memory deficits
with the extent of the parallel use of cannabis or the
combination of ecstasy and cannabis, rather than the use
of ecstasy alone.
44 Elevated cognitive impulsivity and
diminished executive control were also demonstrated in
some studies; however, these results have been less con-
sistent.
44,94-96Although several studies and particularly the
earlier studies suffered from significant methodological
limitations such as polydrug use, short abstinence peri-
ods, poorly matched control groups, and lack of toxico-
logical analyses for verification of the subjects’ reports,
a number of more recent investigations were carefully
designed and conducted, and their results have been
similar.
44-92
The consistency of the data on memory functions and
the association of performance with the extent of previ-
ous ecstasy use are highly suggestive of a residual neu-
rotoxic effect of MDMA. It is possible that the hip-
pocampus may be particularly vulnerable to the
neurotoxic effects of MDMA, and this may explain why
residual effects are most consistent in the memory
domain.
97-98This interpretation is in line with the animal
experimental data, which demonstrated particularly
strong and long-lasting neurotoxic effects of MDMA in
the hippocampus,
11 and a stimulatory role of 5-HT for
neurogenesis in the hippocampus.
49
Interestingly, three studies in current and former
MDMA users with an abstinence period of several
months or even years reported similar or even poorer
memory performance in the former MDMA users,
68,70,99
although SERT availability was only reduced in current
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68-70 Two longitudinal studies yielded conflicting
results: a small study in 15 ecstasy users reported mem-
ory decline after continued use and improvement after
abstinence over 36 months,
100-101 but a larger study in 38
ecstasy users reported no further deterioration of mem-
ory performance after continued use and no improve-
ment after abstinence over 18 months.
102Although these
results may be interpreted as evidence against neuro-
toxicity-related memory decline, it is still possible that
memory deficits in ecstasy users persist even after 18
months of abstinence because, as shown in primate stud-
ies,
11 regeneration of serotonergic axons may take a long
time and may remain incomplete. In addition, the func-
tional consequences of neurotoxic lesions observed fol-
lowing a threshold use of ecstasy may manifest them-
selves in binary (yes/no) manner. Compensatory neural
mechanisms that might develop could possibly explain
the absence of functional deterioration despite subse-
quent “enlargement” of the neurotoxic lesions. This view
would be in line both with findings of a dose-dependent
memory deficit in cross-sectional studies comparing
ecstasy users with control samples, and with the finding
of stable performance in the larger within-subject longi-
tudinal study.
102
Finally, findings from the only prospective study to date
do support this view (part of the Netherlands XTC
Toxicity [NeXT] study). A large number of young sub-
jects who socialized in the drug scene, but had not yet
used amphetamines or ecstasy, were followed up and re-
examined after a mean period of 3 years' follow-up.
103
Although the 58 novice MDMA users reported only
very sporadic and low-dose use of MDMA in the follow-
up period (mean 3.2, median 1.5 tablets) they failed to
demonstrate retest improvements in verbal memory
shown by the persistent MDMA-naive group of 60 sub-
jects.
103This finding suggests that even very low MDMA
doses may be associated with persisting alterations in
memory and learning functions. Although the clinical
relevance of this subtle finding is clearly limited, long-
term negative consequences are conceivable. In conclu-
sion, the linkage between ecstasy use and memory
decline is considered probable at this stage.
Studies in amphetamine users
Compared with MDMA, the literature on amphetamine
related neurotoxicity in humans is limited, but the num-
ber of publications has been constantly increasing over
the last few years. Initial small studies with PET
(regional glucose metabolic rate (rMRGlu), DAT, and
D2 receptor availability), SPECT (DAT availability) and
MR spectroscopy techniques suggested that heavy use
of stimulants may also be neurotoxic in humans and that
alterations may persist over prolonged periods of time.
104-109
Reduced levels of striatal DAT were found in former
METH users even 3 years or more after last use,
104 and
they were found to be associated with a longer duration
of speed use.
106 In a preliminary longitudinal study in five
former speed users, rMRGlu was assessed after 6
months and again after 12 to 17 months of abstinence.
During this follow-up period the initially reduced
MRGlu rose in the thalamus, but remained low in the
striatum, caudate, and nucleus accumbens.
109
Two recent larger MR spectroscopy studies with 24
110
and 36
111 currently abstinent METH users reported low
levels of the neuronal marker NAA (NAA/creatine
ratio) in the anterior cingulate even after very long peri-
ods of abstinence of several years.
110 In contrast, the
choline/NAA values were abnormally high in the users
with relative short abstinence time, but they normalized
after 1 year of abstinence. This finding suggests that fol-
lowing cessation of METH use, adaptive changes occur,
which may contribute to some degree of normalization
of neuronal structure and function.
110 A structural MRI
study in 22 METH users and 21 controls revealed
smaller hippocampal volumes and significant white-mat-
ter hypertrophy in the METH group.
112 Finally, the
largest cross-sectional study so far demonstrated
enlarged putamen and globus pallidus in 50 METH
users compared with 50 controls.
113 Interestingly, within
the METH group larger basal ganglia volumes were
associated with better cognitive performance and less
cumulative METH usage. Therefore, the authors argued
that the enlarged putamen and globus pallidus might
represent a compensatory response to maintain func-
tion.
113 A recent review of the literature reported
enlarged striatal volumes, reduced concentrations of the
neuronal marker NAA-acetylasparate and total creatine
in the basal ganglia, reduced DAT density, and reduced
dopamine D2 receptors in the striatum, lower levels of
SERT density and vesicular monoamine transporters
(VMAT2) across striatal subregions, and altered brain
glucose metabolism in the limbic and orbitofrontal
regions of METH users.
114
Theoretically, neurotoxic dopaminergic lesions could be
associated with motor, cognitive, and psychopathologi-
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not been demonstrated in METH users.
115 However,
more subtle motor deficits were reported in two stud-
ies.
106,109 The literature on long-term psycho(patho)logi-
cal sequelae of stimulant use is inconclusive. Similarly,
cross-sectional studies in chronic stimulant users demon-
strated relatively low performance in short-term and
episodic memory, frontal executive control, and planning
abilities.
111,116-122 However, it is not clear whether these
deficits are a consequence of the use of stimulants or
whether they reflect pre-existing low cognitive abilities
in people who become drug users later in life. 
Nevertheless, reduced DAT densities and longer dura-
tion of METH use were associated with poorer perfor-
mance in both fine motor and memory tasks in 15 cur-
rently abstinent METH users.
106Also, the normalization
of rMRGlu in the thalamus was associated with an
improvement of motor and memory performance after
long-term abstinence of 1 year and more.
109 Finally,
reduced attentional control (ie, increased Stroop inter-
ference) was shown to correlate with levels of NAA-Cr
within the anterior cingulate in METH users, but not in
controls.
111 In conclusion, the limited evidence to date
suggests that persisting neurotoxic brain damage is con-
ceivable in METH users, especially in heavy users with
binge use patterns. More studies with longitudinal and
prospective designs are clearly needed. 
Conclusions
Ecstasy (MDMA) and stimulant amphetamines (METH
and AMPH) are popular drugs of abuse and they are
neurotoxic in animal studies. High and repeated doses
of MDMA cause selective and long-lasting degeneration
of 5-HT axon terminals in several brain regions, whereas
METH and AMPH damage both serotonergic and
dopaminergic neurons. Although the doses taken recre-
ationally are considerably lower than the doses typically
given in animal studies, some users exhibit compulsive
binge use behaviors that may well correspond to the ani-
mal doses. In addition, polydrug use and the typical envi-
ronment of use (hot, overcrowded, and noisy rooms,
extensive physical exercise in the form of dancing) may
well potentiate the neurotoxic effects of the drugs. 
Studies with drug users demonstrated associations of
subtle alterations in brain structure and 5-HT brain
parameters with MDMA use. Similarly, subtle cognitive
dysfunctions, particularly in the memory and learning
domain, were also found to be associated with ecstasy
use. Although the results are not entirely consistent,
these associations were replicated in many well-
designed, controlled studies including longitudinal and
one prospective investigation. Moreover, the only
prospective study to date demonstrated structural brain
alterations and subtle memory dysfunction, even after
minimal exposure to MDMA.
59,103Although most ecstasy
users do not suffer cognitive impairment of clinically rel-
evant proportions, and even heavy users initially appear
mostly unimpaired in their everyday life, several cases
with severe deficits have also been reported.
123-124
Moreover, there is concern that the memory deficits of
ecstasy users—although subtle and mostly subclinical—
and the possible underlying hippocampal dysfunction
might help accelerate the normal brain ageing process
and constitute a risk factor for earlier onset and/or more
severe age-related memory decline in later years.
44
Regarding METH-induced neurotoxicity, evidence from
studies with drug users is relatively scarce and still pre-
liminary. However, there are early indications that at
least heavy METH use may also be followed by alter-
ations in brain structure, dopaminergic parameters, and
cognitive function.
In light of the popularity of ecstasy and stimulants
among young people, questions around their neurotoxic
effects on the brain remain highly topical. To date, the
message we have to convey to young people in infor-
mation campaigns is: “MDMA and amphetamine neu-
rotoxicity for humans is not yet proven, but it is highly
likely.” Further longitudinal and prospective studies are
clearly needed. ❏
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Neurotoxicidad de las drogas de abuso: 
el caso de las metilendioxianfetaminas
(MDMA, éxtasis) y las anfetaminas 
estimulantes
El éxtasis (MDMA, 3,4 metilendioximetanfetamina),
y los estimulantes metanfetamínicos (METH, “speed”)
y anfetamínicos  son drogas frecuentes entre los jóve-
nes, especialmente en lugares de baile. Cuando el
MDMA los estimulantes anfetamínicos son adminis-
tradas en altas dosis a animales de laboratorio resul-
tan claramente neurotóxicas. El MDMA produce lesio-
nes selectivas y persistentes de los terminales
nerviosos serotoninérgicos centrales, mientras que las
anfetaminas dañan tanto los sistemas serotoninérgi-
cos como dopaminérgicos. En los últimos años la pre-
gunta acerca de la neurotoxicidad inducida por el
éxtasis y las posibles secuelas funcionales ha sido tema
de algunos estudios con usuarios de drogas. A pesar
de los grandes problemas metodológicos, la amplia
evidencia sugiere que existen alteraciones residua-
les de la transmisión serotoninérgica en usuarios de
MDMA, aunque puede conseguirse cierta recupera-
ción parcial después de una abstinencia prolongada.
Sin embargo, las secuelas funcionales pueden persis-
tir aun después de largos períodos de abstinencia. A
la fecha, los hallazgos más consistentes asocian los
deterioros cognitivos leves, especialmente las altera-
ciones de memoria con el uso de éxtasis.  En con-
traste, los estudios acerca de los posibles efectos neu-
rotóxicos a largo plazo por el uso de estimulantes han
sido relativamente escasos. La evidencia preliminar
sugiere que las alteraciones del sistema dopaminér-
gico pueden persistir aun después de años de absti-
nencia de METH y pueden asociarse con déficit en el
rendimiento motor y cognitivo. En este artículo se
revisará la literatura dedicada a estudios en humanos. 
Neurotoxicité des substances à l’origine
d’abus: cas des méthylènedioxyamphétamines
(MDMA, ecstasy) et des amphétamines 
stimulantes
L’ecstasy (MDMA, 3,4-méthylènedioxyméthamphé-
tamine) et les stimulants méthamphétaminiques
(METH, speed) et amphétaminiques sont des drogues
courantes chez les jeunes, surtout dans les milieux
festifs. Administrées à dose élevée à des animaux de
laboratoire, la MDMA et les amphétamines stimu-
lantes sont clairement neurotoxiques. La MDMA pro-
voque des lésions sélectives et persistantes des ter-
minaisons nerveuses centrales sérotoninergiques et
les amphétamines lèsent à la fois les systèmes séro-
toninergique et dopaminergique. Ces dernières
années, plusieurs études ont traité la question de la
neurotoxicité de l’ecstasy et des séquelles éventuelles
chez les consommateurs de cette drogue. Malgré
d’importants problèmes méthodologiques, l’essen-
tiel des arguments sont en faveur de modifications
résiduelles de la transmission sérotoninergique chez
les consommateurs de MDMA, récupérables en par-
tie après une longue abstinence. Cependant, même
après un arrêt prolongé, des séquelles fonctionnelles
peuvent persister. Aujourd’hui les résultats les plus
constants font état de déficits cognitifs subtils avec
l’ecstasy, surtout mnésiques. À l’opposé, les études
sur les éventuels effets neurotoxiques à long terme
de la consommation de stimulant sont relativement
rares. Des résultats préliminaires montrent que les
modifications du système dopaminergique persis-
tent, même après des années d’abstinence de METH,
persistance qui peut être associée à des déficits des
performances motrices et cognitives. Dans cet article,
nous passons en revue la littérature centrée sur les
études chez l’homme.
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